Administering

Off-label or unlicensed product use under HMR 2012 exemptions

8 April 2026A legal position summary regarding the sale, supply or administration of off-label/unlicensed products under Schedule 17 of the Human Medicines Regulations 2012

Off label medicine use under a Patient Group Direction

8 April 2026This article explains the legislation and guidance on the use of PGDs when a licensed medicine is to be used outside its licence ('off-label').

Occupational exposure to monoclonal antibodies

22 October 2025Understanding potential exposure to monoclonal antibodies (mAb) informs the occupational risk assessment

Non-acute settings with healthcare input and transcribing

28 January 2025Consideration needs to be given to the risk factors particularly associated with transcribing in non-acute settings with healthcare input

Mixing of medicines and Patient Group Directions

10 November 2025This article provides advice on the legal considerations required when considering mixing medicines to be supplied or administered under a PGD.

Minimising risks associated with administration of injectable iron

14 August 2025Administration of injectable iron has a risk of hypersensitivity and skin staining. Mitigation strategies can help minimise harm.

Medicine administration by registered and non-registered staff

30 September 2025Administration of medicines needs to be undertaken by appropriately trained healthcare staff operating under a legal governance framework

Managing the risks of using effervescent tablets in children

11 February 2026Careful use of effervescent or soluble tablets to deliver part tablet doses for children and neonates can minimise risks of toxicity or suboptimal therapy.

Managing problems when using transdermal patches

5 May 2026Guidance on adhesion, skin reactions, missing, omitted or delayed application, dosing intervals, switching, accidental exposure, and MRI scan considerations.

Managing medicines safely in clinical areas

17 December 2025Medicines-related processes in clinical areas must be designed to minimise the risk of medication errors and patient harm.